You gave all the reasons why this bill is actually in the interests of the brand-name pharmaceuticals: they would get royalties; they wouldn't be cannibalizing their own markets, and so on. So why, in your view, are they so against the bill? What is the main reason? If it's actually a good business proposition for them, what's the sticking point?
On October 21st, 2010. See this statement in context.